Advanced Aesthetic Technologies, Inc. Announces the Treatment of the First Patient in a Pivotal Clinical Trial in China with their Algeness(R) VL (2.5% Agarose Gel) Filler for the Correction of Moderate to Severe Nasolabial Folds

PR90282

BROOKLINE, Mass., June 24, 2021 /PRNewswire=KYODO JBN/--

  -- This new clinical trial is being conducted through their partnership with

     Lanzhou Biotechnique Development Co., LTD (LanDev) and their parent

     company China National Biotec Group Co., LTD (CNBG) and will be used to

     seek marketing approval in China

Advanced Aesthetic Technologies, Inc. (AAT), a leader in aesthetic gel implant

technology, is proud to announce the initiation of a clinical trial for their

Algeness(R) VL (2.5% Agarose Gel) Filler in China in partnership with Lanzhou

Biotechnique Development Co., LTD (LanDev) and their parent company China

National Biotec Group Co., LTD (CNBG) This study aims to evaluate the

effectiveness and safety of Algeness(R) VL (2.5% agarose gel) in the treatment

of moderate to severe nasolabial folds with commercially available hyaluronic

acid fillers for injection as a control. The study will provide further

clinical evidence for the product to apply for NMPA marketing authorization in

Mainland China.

Logo - https://mma.prnewswire.com/media/1550223/AAT_Logo.jpg

Logo - https://mma.prnewswire.com/media/1550093/CNBG_Logo.jpg  

According to Doug Abel, CEO of AAT, "China's aesthetics market is growing

faster than the global market. The size of the Chinese population and

relatively low market penetration of aesthetics and filler treatments in China

present enormous potential for future growth. Our novel Algeness(R) range of

dermal fillers is the first 100% natural, biocompatible and fully biodegradable

filler on the market to date, which differentiates it from other injectable

products. We are very pleased to commence the pursuit of registration in China

through our strategic partner, Lanzhou Biotechnique Development Co., LTD

(LanDev) and their parent company China National Biotec Group Co., LTD (CNBG)."

From 2015 to 2019, the global aesthetic medicine market grew steadily, with a

compound annual growth rate (CAGR) of around 8.2%. China market grew from RMB

64.8 billion in 2015 to RMB 176.9 billion in 2019 - an impressive 28.7% CAGR.

The domestic market is poised to grow at a 15.2% CAGR between 2020 and 2023

(versus 7% globally), following a period of adjustment. (1)

Wu Qiang, General Manager of Lanzhou Biotechnique Development Co. Ltd

commented, "We are proud to work with the AAT team to bring this revolutionary

injectable product to the Chinese market. We believe the distinct advantages

and high safety profile of the Algeness(R) gel filler will resonate with

aesthetic physicians and introduces a new category of biodegradable products to

our growing portfolio."

Algeness(R) is a patented family of fully resorbable injectable gel implant

dermal fillers that are 100% natural, providing advantages in terms of safety,

skin rejuvenation, and natural looking results both at rest and during facial

movement. Typical clinical advantages include minimal swelling upon injection

and immediately visible results. Algeness(R) holds a CE Mark and is currently

distributed in over 30 countries worldwide.

About Advanced Aesthetic Technologies, Inc.

AAT is a fast growing, global corporation developing new technologies for

aesthetic medicine. Our lead products, the Algeness(R) family of injectable

implants, are the culmination of more than 10 years of scientific and clinical

research and were developed with the goal of providing aesthetic injectors

advances in the ability to achieve deep structural support, clean definition,

and exceptional clinical outcomes where the result at the time of treatment is

the final outcome. Algeness(R) is a 100% natural and biodegradable filler based

on purified agarose with a differentiated clinical and safety performance

profile. AAT continuously invests in research and product development to expand

the scientific knowledge on Algeness(R) and agarose as well as in pursuit of

new and innovative technologies to enhance aesthetic medicine and expand our

product portfolio. Algeness(R) is CE Marked, has multiple additional country

level registrations, and is currently available in over 30 countries. AAT is in

the process of pursuing registration in the US through the FDA. www.algeness.com

About Lanzhou Biotechnique Development Co., LTD (LanDev) and their parent

company China National Biotec Group Co., LTD (CNBG)

China National Biotec Group Co., LTD (CNBG), founded in 1919, is a wholly owned

subsidiary of China National Pharmaceutical Group Co., Ltd., one of the world's

top 500 enterprises. As a comprehensive biopharmaceutical enterprise, CNBG has

a long history with complete product lines and large scale, integrating

scientific research, production, sales, and postgraduate training. CNBG's

product lines cover six major biological product fields, including human

vaccines, blood products, medical beauty, animal health, antibody drugs, and

medical diagnosis. www.cnbg.com.cn

Lanzhou Biotechnique Development Co., LTD (LanDev), is a leading medical and

beauty health professional company in China. Its business covers botulinum

toxin, hyaluronic acid, collagen, laser beauty equipment, etc. LanDev is the

exclusive manufacturer of botulinum toxin A (BTXA)-Hengli(R) in China that

enjoys an approximate 70% market share for BTXA in China. Hengli(R) has been

sold for more than 20 years and has accumulated more than ten million of

clinical use cases. At the same time, LanDev is the exclusive distributor in

mainland China of Princess, the hyaluronic acid fillers produced by

CROMA-Pharma GmbH, an Austrian company. LanDev has also established an indepth

strategic partnership with Cynosure, an industry leading U.S. company. LanDev

is becoming an innovative enterprise leading the development of the domestic

industry with its growing international competitiveness and social respects.

Contact: filler@algeness.com

(1)

https://www2.deloitte.com/cn/en/pages/life-sciences-and-healthcare/articles/china-aesthetic-medicine-market-outlook.html

SOURCE: Advanced Aesthetic Technologies, Inc.